We intend to move forward with our human-health focus, leaning towards mental health parity through developing potential treatments for depression, schizophrenia, and dementia.

These conditions are urgent global health challenges, and we have already been actively involved in clinical trial development. We will continue to push forward with innovative and breakthrough therapies, striving to bring new hope to patients.

In addressing infectious diseases (e.g. influenza, COVID-19), we plan to tackle these pandemics through various approaches, including FDA-approved pharmaceuticals, and health supplements.

As we move forward, we aim to address these critical health challenges with an efficient development process. Our goal is to bypass, when scientifically justified, the traditional barriers that often involve decade-long delays and billions of dollars in costs, and contribute our efforts toward meeting unmet health needs.